Data-driven techniques for translational neuroscience and personalized neuro-health
Organizations: Department of Mathematics and Statistics, University of Maryland Baltimore County, Baltimore, Maryland, USA · Department of Mathematics and Statistics, Texas Tech University, Lubbock, Texas, USA · Department of Information Systems, University of Maryland Baltimore County, Baltimore, Maryland, USA · Center for Magnetic Resonance Research, Department of Radiology, University of Minnesota, Minneapolis, Minnesota, USA ·
Abstract
Neurodegenexrative diseases such as Alzheimer's disease and Parkinson's disease are diagnosed most reliably only after substantial, often irreversible, neuronal loss has already occurred, creating an urgent need for quantitative tools that can detect subtle, early, and individual-specific brain changes from neuroimaging data. This review surveys a broad and rapidly evolving toolkit of data-driven techniques for translational neuroscience and personalized neuro-health, organized around four complementary methodological pillars. Throughout, we emphasize how these methodologically diverse approaches converge on a common translational goal: personalized, mechanistically grounded, and clinically actionable models of individual brain health, and we close by discussing the principal open statistical, computational, and clinical challenges that remain.
Figures & tables
| Notation/Acronym | Definition (expanded form) |
|---|---|
| Neuroscince related terms | |
| ADHD | attention deficit hyperactivity disorder |
| AD | Alzheimer’s disease |
| ADNI | Alzheimer’s Disease Neuroimaging Initiative |
| ASD | autism spectrum disorder |
| dMRI | diffusion magnetic resonance imaging |
| \midrule Node type | ADNI instantiation |
|---|---|
| \midrule Subject | Participant, labelled CN / MCI / AD |
| Brain ROI | FreeSurfer-parcellated regions from T1 MRI (hippocampus, entorhinal cortex, posterior cingulate, precuneus) |
| Imaging measure | Structural MRI volume/thickness, FDG-PET, amyloid-PET ( 18 F-florbetapir), tau-PET ( 18 F-flortaucipir) |
| Fluid biomarker | CSF A 42, t-tau, p-tau181; plasma p-tau |
| Genetic marker | APOE 4 allele count; candidate SNPs; polygenic risk score |
| Cognitive / clinical | MMSE, ADAS-Cog, CDR-SB, RAVLT |
| \midrule Hyperedge | Members it connects | Higher-order rationale |
| Multimodal biomarker profile | Subject its discretised imaging, fluid, genetic, and cognitive markers at a visit | Diagnosis is the joint configuration, not any single pair |
| Subject similarity (kNN) | A subject and its nearest neighbours in one modality’s feature space | Multimodal hypergraph union over modality-specific hyperedges |
| Regional co-atrophy / co-activation | A set of ROIs that jointly deviate (e.g., default-mode network) | Captures network-level dysfunction across many regions at once |
| Longitudinal trajectory | The same subject’s states across visits | Encodes progression CN MCI AD |
| Mechanistic bridge | Genetic, molecular, anatomical, and disease nodes (e.g., APOE–amyloid pathway–medial-temporal ROIs–AD) | Links the cohort hypergraph to an external biomedical KG |
| \midrule |
Neuroimaging
Neuroimaging uses brain measurements and computational methods to map anatomy, activity, connectivity, and disease.
See all 235 papers